Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.
The study led by the Eastern Cooperative Oncology Group (ECOG) and supported by the National Cancer Institute compared combination treatment of oral medications lenalidomide and either high- or low-dose dexamethasone in 445 patients with newly-diagnosed myeloma. Lenalidomide plus high-dose dexamethasone had a one-year survival rate of 86 percent. The comparative therapy using low-dose dexamethasone showed a significantly higher 96.5 percent overall survival rate at one year, with much less toxicity.
"In my opinion, this is the best one-year survival data that I’ve seen in a large phase 3 study in myeloma," says Vincent Rajkumar, M.D., Mayo Clinic hematologist and primary investigator of the ECOG study. "This is a major advance in the treatment of this cancer."
All patients on the high-dose dexamethasone arm of the clinical trial will be moved to the low-dose arm. A successor study using lenalidomide plus high-dose dexamethasone was closed early as a result of these findings.
Source: Mayo Clinic
Related stories:
Scientists use nanomaterials to localize and control drug delivery
Using nanotechnology, scientists from UCLA and Northwestern University have developed a localized and controlled drug delivery method that is invisible to the immune system, a discovery that could provide newer and more effective treatments for cancer and other diseases.
Stem cells make bone marrow cancer resistant to treatment
Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments.
Scientists tackle mystery mountain illness
Experts at the University are studying an illness known as HAPE (high altitude pulmonary oedema), which causes fluid to build up in the lungs can and can occur from as low as 2,500 metres, affecting people of all age groups and fitness levels.
New research provides hope for childhood cancer sufferers
Dr Richard Lock, Head of the Leukaemia Biology Program at the Children’s Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal
Blood.
New research provides hope for childhood cancer sufferers
Scientists investigating drug therapies for children with Acute Lymphoblastic Leukaemia (ALL) have presented new data demonstrating for the very first time that a small molecule called ABT-737 can increase the effectiveness of standard therapies.
New multiple myeloma treatment induced total remission in 33 percent of patients
A study, lead by Dr. Laura Rosiñol, researcher of the
Haematooncology Group of Hospital Clínic-IDIBAPS (Barcelona) in collaboration with Dr Joan Blade, researcher in the same group, administered alternately two drugs (Bortezomid and Dexamethasone) before conducting autologous bone marrow transplantations. The aim of this second phase trial was to assess the treatment’s overall response rate, its toxicity in patients, the possibility of recovery of innate stem cells, and the response kinetics which is calculated by measuring M-protein concentrations in serum and urine. M-protein is associated with myeloma presence.
Stealth particles to target tumors
Stealth nano particles may some day target tumor cells and deliver medication to specific body locations, according to Penn State chemical engineers.